EMC
MCID: EPT010
MIFTS: 49

Epithelial-Myoepithelial Carcinoma (EMC)

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Epithelial-Myoepithelial Carcinoma

MalaCards integrated aliases for Epithelial-Myoepithelial Carcinoma:

Name: Epithelial-Myoepithelial Carcinoma 12 77 54 30 15 41 74
Clear Cell Adenoma 54 74
Epithelial Myoepithelial Carcinoma 54
Glycogen-Rich Adenocarcinoma 54
Monomorphic Clear Cell Tumor 54
Adenocarcinoma, Clear Cell 74
Glycogen-Rich Adenoma 54
Tubular Solid Adenoma 54
Adenomyo-Epithelioma 54
Clear Cell Carcinoma 54
Emc 54

Classifications:



External Ids:

Disease Ontology 12 DOID:5309
NCIt 51 C4199
SNOMED-CT 69 9618003

Summaries for Epithelial-Myoepithelial Carcinoma

MalaCards based summary : Epithelial-Myoepithelial Carcinoma, also known as clear cell adenoma, is related to clear cell renal cell carcinoma and pleomorphic adenoma carcinoma. An important gene associated with Epithelial-Myoepithelial Carcinoma is TAF15 (TATA-Box Binding Protein Associated Factor 15), and among its related pathways/superpathways are MicroRNAs in cancer and Cytoskeleton remodeling Neurofilaments. The drugs Doxorubicin and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, kidney and lymph node, and related phenotypes are Decreased CDKN1A mRNA expression and Decreased CDKN1A mRNA expression

Wikipedia : 77 Epithelial-myoepithelial carcinoma (EMCa) is a rare malignant tumour that typically arises in a salivary... more...

Related Diseases for Epithelial-Myoepithelial Carcinoma

Diseases related to Epithelial-Myoepithelial Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 270)
# Related Disease Score Top Affiliating Genes
1 clear cell renal cell carcinoma 32.9 KRT7 TP53 VIM
2 pleomorphic adenoma carcinoma 30.8 HMGA2 TP53
3 pleomorphic adenoma 30.8 HMGA2 KRT14 TP53 VIM
4 uterine corpus serous adenocarcinoma 30.4 FBXW7 TP53
5 papillary adenocarcinoma 30.3 KRT7 TP53 VIM
6 spindle cell sarcoma 30.3 KRT7 VIM
7 cystic teratoma 30.2 KRT7 TP53
8 metanephric adenoma 30.1 KRT7 VIM
9 carcinosarcoma 30.1 HRAS KRT7 TP53 VIM
10 spindle cell carcinoma 30.0 KRT14 KRT7 VIM
11 necrotizing sialometaplasia 30.0 KRT7 TP53
12 sarcoma 29.9 HRAS NR4A3 TP53 VIM
13 acinar cell carcinoma 29.8 KRT7 TP53
14 transitional cell carcinoma 29.8 HRAS KRT7 TP53
15 myxoid chondrosarcoma 29.8 NR4A3 TAF15
16 adenoid cystic carcinoma 29.6 FBXW7 HRAS KRT14 KRT7 TP53 VIM
17 ovarian clear cell carcinoma 12.6
18 parathyroid transitional clear cell adenoma 12.5
19 clear cell adenoma 12.5
20 water-clear cell adenoma 12.5
21 thymus clear cell carcinoma 12.4
22 hepatocellular clear cell carcinoma 12.2
23 lung clear cell carcinoma 12.2
24 chondrosarcoma, extraskeletal myxoid 12.0
25 clear cell adenocarcinoma 11.7
26 myoepithelial carcinoma 11.2
27 endometrial clear cell adenocarcinoma 11.2
28 fallopian tube clear cell adenocarcinoma 11.2
29 cervical clear cell adenocarcinoma 11.2
30 bile duct clear cell adenocarcinoma 11.2
31 multilocular cystic renal neoplasm of low malignant potential 11.2
32 endometriosis 10.6
33 adenoma 10.6
34 ameloblastic carcinoma 10.4 KRT14 VIM
35 odontoma 10.4 KRT14 VIM
36 parachordoma 10.4 KRT7 VIM
37 secretory meningioma 10.4 KRT7 VIM
38 malignant ectomesenchymoma 10.4 HMGA2 HRAS
39 benign breast adenomyoepithelioma 10.4 KRT14 KRT7
40 adenoid squamous cell carcinoma 10.4 KRT7 VIM
41 ectomesenchymoma 10.4 HMGA2 HRAS
42 breast adenomyoepithelioma 10.4 KRT14 KRT7
43 nodular hidradenoma 10.4 KRT7 VIM
44 hidradenoma 10.4 KRT7 VIM
45 papillary adenoma 10.4 KRT7 VIM
46 oncocytic breast carcinoma 10.4 KRT14 KRT7
47 benign metastasizing leiomyoma 10.3 KRT7 VIM
48 large cell acanthoma 10.3 KRT14 KRT7
49 monophasic synovial sarcoma 10.3 KRT7 VIM
50 apocrine sweat gland neoplasm 10.3 KRT14 KRT7

Graphical network of the top 20 diseases related to Epithelial-Myoepithelial Carcinoma:



Diseases related to Epithelial-Myoepithelial Carcinoma

Symptoms & Phenotypes for Epithelial-Myoepithelial Carcinoma

GenomeRNAi Phenotypes related to Epithelial-Myoepithelial Carcinoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased CDKN1A mRNA expression GR00389-S-1 9.43 FBXW7 TP53
2 Decreased CDKN1A mRNA expression GR00389-S-2 9.43 TP53 HMGA2
3 Increased TP53 mRNA expression GR00389-S-6 8.62 HMGA2 TP53

MGI Mouse Phenotypes related to Epithelial-Myoepithelial Carcinoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.81 FBXW7 HRAS KRT14 KRT7 NR4A3 PLIN1
2 integument MP:0010771 9.5 FBXW7 HRAS KRT14 NR4A3 PLIN1 PLIN2
3 neoplasm MP:0002006 9.02 FBXW7 HRAS KRT14 NR4A3 TP53

Drugs & Therapeutics for Epithelial-Myoepithelial Carcinoma

Drugs for Epithelial-Myoepithelial Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 97)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
2
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 38904 10339178 498142
3
Epirubicin Approved Phase 3 56420-45-2 41867
4
Cisplatin Approved Phase 3,Phase 1 15663-27-1 441203 84093 2767
5
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
6
Doxil Approved June 1999 Phase 3,Phase 2 31703
7 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
8 Topoisomerase Inhibitors Phase 3,Phase 2
9 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
10 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
11 Antimitotic Agents Phase 3,Phase 2
12 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
13
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
14
Sodium Citrate Approved, Investigational Phase 2 68-04-2
15
Sunitinib Approved, Investigational Phase 2,Not Applicable 557795-19-4, 341031-54-7 5329102
16
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
17
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
18
Bevacizumab Approved, Investigational Phase 2,Not Applicable 216974-75-3
19
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177 70789204
20
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
21
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
22
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
23
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
24
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
25
Nintedanib Approved Phase 2 656247-17-5 56843413
26
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60700
27
nivolumab Approved Phase 2 946414-94-4
28
Ipilimumab Approved Phase 2 477202-00-9
29
Pembrolizumab Approved Phase 2 1374853-91-4
30
Durvalumab Approved, Investigational Phase 2 1428935-60-7
31
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
32
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
33
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
34
Trebananib Investigational Phase 2 894356-79-7
35
Lapatinib Approved March 2007, Investigational Phase 2 388082-78-8, 231277-92-2 208908 9941095
36
Tremelimumab Investigational Phase 2 745013-59-6
37 Protein Kinase Inhibitors Phase 2,Not Applicable
38 Chelating Agents Phase 2
39 Citrate Phase 2
40 Calcium, Dietary Phase 2
41 Anticoagulants Phase 2
42 Angiogenesis Modulating Agents Phase 2,Not Applicable
43 Angiogenesis Inhibitors Phase 2,Not Applicable
44 Analgesics Phase 2
45 Anti-Retroviral Agents Phase 2
46 Analgesics, Non-Narcotic Phase 2
47 Anti-HIV Agents Phase 2
48 Interleukin-2 Phase 2
49 Peripheral Nervous System Agents Phase 2
50 Antiviral Agents Phase 2

Interventional clinical trials:

(show all 50)
# Name Status NCT ID Phase Drugs
1 Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer Completed NCT00003749 Phase 3
2 Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer Completed NCT00005583 Phase 3 cisplatin;doxorubicin hydrochloride;epirubicin hydrochloride
3 Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery Completed NCT00002807 Phase 3
4 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer Completed NCT00002493 Phase 3 cisplatin;doxorubicin hydrochloride
5 Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer Completed NCT00006027 Phase 3 cisplatin;paclitaxel
6 Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer Active, not recruiting NCT00411138 Phase 3 cisplatin;carboplatin;Paclitaxel
7 Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Active, not recruiting NCT01672892 Phase 3
8 Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer Unknown status NCT02059265 Phase 2 Dasatinib
9 Liposome-Encapsulated Doxorubicin Citrate and Carboplatin in Treating Patients With Advanced or Metastatic Recurrent Endometrial Cancer Unknown status NCT01100359 Phase 2 carboplatin;liposome-encapsulated doxorubicin citrate
10 A Study of ENMD-2076 in Ovarian Clear Cell Cancers Completed NCT01914510 Phase 2 ENMD-2076
11 Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma Completed NCT01824615 Phase 2 Sunitinib
12 AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib Completed NCT00467025 Phase 2 AMG 386;Sorafenib;AMG 386 placebo IV
13 Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney Completed NCT00853021 Phase 2
14 Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10
15 Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer Completed NCT01196429 Phase 2 Carboplatin;Docetaxel;Paclitaxel;Temsirolimus
16 Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer Completed NCT00719264 Phase 2 RAD001(everolimus);interferon alfa-2a;bevacizumab
17 LBH589 Treatment for Refractory Clear Cell Renal Carcinoma Completed NCT00550277 Phase 2 LBH589
18 Sunitinib in Metastatic Renal Cancer Completed NCT01034878 Phase 2 Sunitinib
19 High-dose Bevacizumab in Advanced Renal Carcinoma Patients Completed NCT00455975 Phase 2 Bevacizumab
20 Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00025467 Phase 2 thalidomide
21 Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer Completed NCT00072176 Phase 2 temsirolimus
22 S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer Completed NCT00003127 Phase 2 amifostine trihydrate;carboplatin;paclitaxel
23 Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer Completed NCT00770185 Phase 2 ridaforolimus
24 Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer Completed NCT00113373 Phase 2 lapatinib ditosylate
25 Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium Recruiting NCT02866370 Phase 2 Nintedanib;Paclitaxel;Pegylated Liposomal Doxorubicin (PLD);Topotecan;Carboplatin;Doxorubicin
26 BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas Recruiting NCT03355976 Phase 2 Nivolumab;Ipilimumab
27 Pembrolizumab and Epacadostat in Treating Patients With Recurrent, Persistent, or Progressive Ovarian Clear Cell Carcinoma Recruiting NCT03602586 Phase 2 Epacadostat
28 A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas Recruiting NCT03405454 Phase 2 durvalumab;standard chemotherapy
29 MEDI4736 Combinations in Metastatic Renal Cell Carcinoma Recruiting NCT02819596 Phase 2 Savolitinib;MEDI4736;Tremelimumab
30 Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment. Recruiting NCT03066427 Phase 2 Sunitinib
31 A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers Recruiting NCT02923934 Phase 2 Ipilimumab;Nivolumab
32 A Study of PLX2853 in Advanced Malignancies. Recruiting NCT03297424 Phase 1, Phase 2 PLX2853
33 A Study of Nivolumab in Selected Uterine Cancer Patients Recruiting NCT03241745 Phase 2 Nivolumab
34 Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02315430 Phase 2 Cabozantinib S-malate
35 TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting NCT00563784 Phase 2 Erlotinib;Carboplatin;Paclitaxel
36 Tazemetostat in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Endometrial Cancer Not yet recruiting NCT03348631 Phase 2 Tazemetostat
37 A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers Terminated NCT00231829 Phase 2 Celecoxib
38 ATN-161 in Advanced Renal Cell Cancer Terminated NCT00131651 Phase 2 ATN-161
39 ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer Completed NCT00056537 Phase 1 ABR-217620
40 Whole-Abdominal Radiation Therapy and Cisplatin in Treating Patients With Stage III or Stage IV Endometrial Cancer That Has Been Removed by Surgery Completed NCT00448643 Phase 1 Cisplatin
41 A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas Active, not recruiting NCT01625351 Phase 1 alemtuzumab;fludarabine;sirolimus;Busulfan;melphalan
42 A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma Terminated NCT02837991 Phase 1 CDX-014
43 Role of Biomarkers in Endometrial Cancer Recurrence in Samples From Patients With Stage II, Stage III, or Stage IV Endometrial Cancer Unknown status NCT01150682
44 Ovarian Clear Cell Adenocarcinoma Review Completed NCT02129036
45 Endometrial Cancer and Fractalkine-receptor Axis of Fractalkine Completed NCT02774395
46 Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy Completed NCT02282579 Pazopanib
47 The Role of Hypoxia as a Selective Pressure for TP53 Mutations Recruiting NCT03466034
48 Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma Active, not recruiting NCT01582204 Not Applicable 124IcG250
49 Feasibility Study: Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients Active, not recruiting NCT01504126 Not Applicable Propranolol;Chemotherapy
50 Endometriosis and Frequency of Endometriosis-associated Ovarian Carcinomas (EAOC) Withdrawn NCT01732432

Search NIH Clinical Center for Epithelial-Myoepithelial Carcinoma

Genetic Tests for Epithelial-Myoepithelial Carcinoma

Genetic tests related to Epithelial-Myoepithelial Carcinoma:

# Genetic test Affiliating Genes
1 Epithelial-Myoepithelial Carcinoma 30 NR4A3 TAF15

Anatomical Context for Epithelial-Myoepithelial Carcinoma

MalaCards organs/tissues related to Epithelial-Myoepithelial Carcinoma:

42
Salivary Gland, Kidney, Lymph Node, Tongue, Ovary, Breast, Trachea

Publications for Epithelial-Myoepithelial Carcinoma

Articles related to Epithelial-Myoepithelial Carcinoma:

(show top 50) (show all 200)
# Title Authors Year
1
Sinonasal epithelial-myoepithelial carcinoma: Report of a novel subsite and review of the literature. ( 29977654 )
2018
2
The So-Called Aggressive Digital Papillary Adenocarcinoma Is Epithelial-Myoepithelial Carcinoma. ( 29384814 )
2018
3
MYB Translocation Status in Salivary Gland Epithelial-Myoepithelial Carcinoma: Evaluation of Classic, Variant, and Hybrid Forms. ( 29135517 )
2018
4
Metaplastic breast carcinoma composed of epithelial-myoepithelial carcinoma and squamous cell carcinoma: A case report. ( 29642184 )
2018
5
Epithelial-myoepithelial carcinoma of the lung: a case report. ( 29987577 )
2018
6
Epithelial-Myoepithelial Carcinoma Presenting as a Pseudo Veno-Lymphatic Malformation. ( 30080758 )
2018
7
Epithelial-myoepithelial carcinoma: a population-based survival analysis. ( 30127663 )
2018
8
Primary epithelial-myoepithelial carcinoma of the lung with cavitary lesion: A case report. ( 30155254 )
2018
9
Dedifferentiation of oncocytic epithelial-myoepithelial carcinoma to mucoepidermoid carcinoma in parotid gland: A rare case report. ( 30303150 )
2018
10
Epithelial-Myoepithelial Carcinoma in a Canine Salivary Gland. ( 30502796 )
2018
11
Mammary Epithelial-Myoepithelial Carcinoma: Report of a Case With HRAS and PIK3CA Mutations by Next-Generation Sequencing. ( 30585117 )
2018
12
Radiation-associated epithelial-myoepithelial carcinoma among five secondary malignancies: A case report and review of literature. ( 30622928 )
2018
13
Epithelial-myoepithelial carcinoma with high-grade transformation of parotid gland: A case report and literature review. ( 29245272 )
2017
14
Epithelial-Myoepithelial Carcinoma of the Base of Tongue with Possible Lung Metastases. ( 29085691 )
2017
15
Endobronchial epithelial-myoepithelial carcinoma of the lung. ( 29196470 )
2017
16
Salivary epithelial-myoepithelial carcinoma: clinical, morphological and molecular features. ( 28635988 )
2017
17
Epithelial Myoepithelial Carcinoma of the Nasal Cavity: Clinical, Histopathological, and Immunohistochemical Distinction of a Case Report. ( 29237344 )
2017
18
First case report of a curative wedge resection in epithelial-myoepithelial carcinoma of the lung. ( 28653299 )
2017
19
Carcinoma Ex Pleomorphic Adenoma of the Lacrimal Gland with Epithelial-Myoepithelial Carcinoma Histologic Type. ( 26934566 )
2016
20
Going beyond "Basaloid neoplasm": Fine needle aspiration cytology of epithelial-myoepithelial carcinoma of the parotid gland. ( 26798976 )
2016
21
A rare case of primary peripheral epithelial myoepithelial carcinoma of lung: Case report and literature review. ( 27583848 )
2016
22
Epithelial-myoepithelial carcinoma of the minor salivary glands: a case report and review of the literature. ( 27599278 )
2016
23
Sinonasal epithelial-myoepithelial carcinoma: A case report. ( 27773082 )
2016
24
Fine-Needle Aspiration of Epithelial-Myoepithelial Carcinoma of the Parotid Gland With Prominent Adenoid Cystic Carcinoma-Like Cribriform Features: Avoiding a Diagnostic Pitfall. ( 27614667 )
2016
25
Epithelial-Myoepithelial Carcinoma of the Salivary Gland Harboring HRAS Codon 61 Mutations With Lung Metastasis. ( 26675036 )
2016
26
Cytomorphologic Attributes of Epithelial Myoepithelial Carcinoma of Nasal Cavity - A Rare Tumor with Unusual Clinical Presentation. ( 27790447 )
2016
27
Epithelial-myoepithelial carcinoma arising from the subglottis: a case report and review of the literature. ( 26922486 )
2016
28
Bilateral epithelial-myoepithelial carcinoma of the parotid glands. ( 26314935 )
2015
29
High-grade epithelial-myoepithelial carcinoma of the parotid gland with mucous cell differentiation. ( 26037059 )
2015
30
Salivary Gland Epithelial-Myoepithelial Carcinoma with High-Grade Transformation in a Dog. ( 26223938 )
2015
31
Nasal epithelial myoepithelial carcinoma: An unusual cause of epiphora, a case report and review of the literature. ( 26302736 )
2015
32
Epithelial-myoepithelial carcinoma of lacrimal gland from an ex pleomorphic adenoma. ( 26231189 )
2015
33
Epithelial-Myoepithelial Carcinoma of the Salivary Glands: An Analysis of 246 Cases. ( 26195572 )
2015
34
A Rare Case of Bronchial Epithelial-Myoepithelial Carcinoma with Solid Lobular Growth in a 53-Year-Old Woman. ( 26508939 )
2015
35
Primary epithelial-myoepithelial carcinoma of the lung: A case report demonstrating high-grade transformation-like changes. ( 26170995 )
2015
36
Endobronchial laser ablation in the management of epithelial-myoepithelial carcinoma of the trachea. ( 26744686 )
2015
37
Parotid epithelial-myoepithelial carcinoma: an unexpected intraoperative finding. ( 25809427 )
2015
38
Global transcriptome and sequenome analysis of formalin-fixed salivary epithelial-myoepithelial carcinoma specimens. ( 25546727 )
2015
39
Tracheal epithelial-myoepithelial carcinoma associated with sarcoid-like reaction: A case report. ( 26029574 )
2015
40
Epithelial-myoepithelial Carcinoma - Review of Clinicopathological and Immunohistochemical Features. ( 25841941 )
2015
41
Epithelial-myoepithelial carcinoma metastasis to the thoracic spine. ( 26474503 )
2015
42
Epithelial-myoepithelial carcinoma of the nasopharynx: A case report and review of the literature. ( 26622597 )
2015
43
Iodine-125 brachytherapy for the treatment of a large parotid epithelial-myoepithelial carcinoma in a child. ( 25240907 )
2014
44
An unusual case of epithelial-myoepithelial carcinoma of the parotid gland radiologically simulating a benign lesion. ( 24959051 )
2014
45
Epithelial-myoepithelial carcinoma of the hypopharynx: A rare case. ( 24932273 )
2014
46
Case study of a parotid gland adenocarcinoma dedifferentiated from epithelial-myoepithelial carcinoma. ( 25276459 )
2014
47
Epithelial-myoepithelial carcinoma of the parotid gland: Clinicopathological aspect, diagnosis and surgical consideration. ( 24987609 )
2014
48
Sebaceous epithelial-myoepithelial carcinoma of the parotid gland: a case report of a new histologic variant. ( 24929841 )
2014
49
Radiation-induced epithelial-myoepithelial carcinoma in a patient previously treated with mantle-field radiation therapy for Hodgkin's Lymphoma. ( 25242451 )
2014
50
Acquired von Willebrand's disease associated with epithelial myoepithelial carcinoma of the parotid salivary gland. ( 25096657 )
2014

Variations for Epithelial-Myoepithelial Carcinoma

Cosmic variations for Epithelial-Myoepithelial Carcinoma:

9 (show top 50) (show all 237)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM1658946 VWA5B1 salivary gland,parotid,carcinoma,NS c.1486G>A p.V496I 1:20330897-20330897 0
2 COSM5030964 VHL salivary gland,parotid,carcinoma,NS c.319C>T p.R107C 3:10142166-10142166 0
3 COSM1659032 TXNRD3 salivary gland,parotid,carcinoma,NS c.412A>G p.K138E 3:126647293-126647293 0
4 COSM5030953 TP53 salivary gland,parotid,carcinoma,NS c.38C>T p.P13L 17:7676557-7676557 0
5 COSM11564 TP53 salivary gland,parotid,carcinoma,NS c.742C>G p.R248G 17:7674221-7674221 0
6 COSM44850 TP53 salivary gland,parotid,carcinoma,NS c.494A>T p.Q165L 17:7675118-7675118 0
7 COSM43632 TP53 salivary gland,parotid,carcinoma,NS c.493C>T p.Q165* 17:7675119-7675119 0
8 COSM11305 TP53 salivary gland,parotid,carcinoma,NS c.809T>C p.F270S 17:7673811-7673811 0
9 COSM44640 TP53 salivary gland,parotid,carcinoma,NS c.782+1G>T p.? 17:7674180-7674180 0
10 COSM45307 TP53 salivary gland,parotid,carcinoma,NS c.309C>A p.Y103* 17:7676060-7676060 0
11 COSM307275 TP53 salivary gland,NS,carcinoma,myoepithelial carcinoma c.96+1G>T p.? 17:7676381-7676381 0
12 COSM43687 TP53 salivary gland,parotid,carcinoma,NS c.641A>G p.H214R 17:7674890-7674890 0
13 COSM11196 TP53 salivary gland,parotid,carcinoma,NS c.734G>T p.G245V 17:7674229-7674229 0
14 COSM43814 TP53 salivary gland,parotid,carcinoma,NS c.587G>C p.R196P 17:7674944-7674944 0
15 COSM43596 TP53 salivary gland,parotid,carcinoma,NS c.841G>A p.D281N 17:7673779-7673779 0
16 COSM43918 TP53 salivary gland,parotid,carcinoma,NS c.809T>A p.F270Y 17:7673811-7673811 0
17 COSM10886 TP53 salivary gland,parotid,carcinoma,NS c.310C>T p.Q104* 17:7676059-7676059 0
18 COSM10690 TP53 salivary gland,parotid,carcinoma,NS c.473G>A p.R158H 17:7675139-7675139 0
19 COSM46283 TP53 salivary gland,parotid,carcinoma,NS c.569C>A p.P190H 17:7674962-7674962 0
20 COSM12013 TP53 salivary gland,parotid,carcinoma,NS c.731G>C p.G244A 17:7674232-7674232 0
21 COSM10646 TP53 salivary gland,parotid,carcinoma,NS c.725G>A p.C242Y 17:7674238-7674238 0
22 COSM10704 TP53 salivary gland,parotid,carcinoma,NS c.844C>T p.R282W 17:7673776-7673776 0
23 COSM44094 TP53 salivary gland,parotid,carcinoma,NS c.716A>G p.N239S 17:7674247-7674247 0
24 COSM43797 TP53 salivary gland,parotid,carcinoma,NS c.550G>C p.D184H 17:7675062-7675062 0
25 COSM46282 TP53 salivary gland,parotid,carcinoma,NS c.501G>C p.Q167H 17:7675111-7675111 0
26 COSM10779 TP53 salivary gland,parotid,carcinoma,NS c.818G>T p.R273L 17:7673802-7673802 0
27 COSM44853 TP53 salivary gland,parotid,carcinoma,NS c.661G>A p.E221K 17:7674870-7674870 0
28 COSM11059 TP53 salivary gland,parotid,carcinoma,NS c.713G>A p.C238Y 17:7674250-7674250 0
29 COSM12193 TP53 salivary gland,parotid,carcinoma,NS c.668C>T p.P223L 17:7674863-7674863 0
30 COSM5030954 TP53 salivary gland,parotid,carcinoma,NS c.260C>T p.P87L 17:7676109-7676109 0
31 COSM10939 TP53 salivary gland,parotid,carcinoma,NS c.832C>T p.P278S 17:7673788-7673788 0
32 COSM10758 TP53 salivary gland,parotid,carcinoma,myoepithelial carcinoma c.659A>G p.Y220C 17:7674872-7674872 0
33 COSM10654 TP53 salivary gland,parotid,carcinoma,NS c.637C>T p.R213* 17:7674894-7674894 0
34 COSM1659070 TOMM34 salivary gland,parotid,carcinoma,NS c.555T>A p.P185P 20:44948873-44948873 0
35 COSM34221 TIE1 salivary gland,parotid,carcinoma,NS c.2050G>C p.A684P 1:43313257-43313257 0
36 COSM6982985 TET2 salivary gland,parotid,carcinoma,NS c.650C>T p.S217F 4:105234592-105234592 0
37 COSM6975881 TCF7L2 salivary gland,parotid,carcinoma,NS c.814C>T p.P272S 10:113151005-113151005 0
38 COSM1658982 TANGO6 salivary gland,parotid,carcinoma,NS c.352G>C p.G118R 16:68907540-68907540 0
39 COSM1658977 STXBP3 salivary gland,parotid,carcinoma,NS c.1275G>C p.R425S 1:108796645-108796645 0
40 COSM6906905 STAT5B salivary gland,parotid,carcinoma,NS c.1982G>A p.G661E 17:42207653-42207653 0
41 COSM6975971 STAT5A salivary gland,parotid,carcinoma,NS c.1484C>T p.P495L 17:42306251-42306251 0
42 COSM6920823 STAG2 salivary gland,NS,carcinoma,myoepithelial carcinoma c.1808G>A p.G603E 23:124063192-124063192 0
43 COSM1659007 SMARCA2 salivary gland,parotid,carcinoma,NS c.3476G>T p.R1159L 9:2115841-2115841 0
44 COSM1389051 SMAD4 salivary gland,parotid,carcinoma,NS c.993G>A p.M331I 18:51065460-51065460 0
45 COSM14163 SMAD4 salivary gland,parotid,carcinoma,NS c.931C>T p.Q311* 18:51059892-51059892 0
46 COSM5030960 SMAD4 salivary gland,parotid,carcinoma,NS c.527G>A p.G176E 18:51054853-51054853 0
47 COSM4468820 SMAD4 salivary gland,parotid,carcinoma,NS c.1565C>T p.P522L 18:51078373-51078373 0
48 COSM1659093 SLC25A13 salivary gland,parotid,carcinoma,NS c.888G>A p.L296L 7:96189339-96189339 0
49 COSM1658944 SIK2 salivary gland,parotid,carcinoma,NS c.1387G>A p.E463K 11:111719895-111719895 0
50 COSM1658998 SF3B1 salivary gland,parotid,carcinoma,NS c.1873C>A p.R625S 2:197402760-197402760 0

Expression for Epithelial-Myoepithelial Carcinoma

Search GEO for disease gene expression data for Epithelial-Myoepithelial Carcinoma.

Pathways for Epithelial-Myoepithelial Carcinoma

Pathways related to Epithelial-Myoepithelial Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.93 HMGA2 HRAS TP53 VIM
2
Show member pathways
11.47 KRT14 KRT7 VIM
3 11.19 HMGA2 NR4A3 TAF15 TP53
4 10.95 FBXW7 HRAS TP53

GO Terms for Epithelial-Myoepithelial Carcinoma

Cellular components related to Epithelial-Myoepithelial Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.32 FBXW7 HMGA2 HRAS KRT14 KRT7 NR4A3
2 intermediate filament GO:0005882 9.13 KRT14 KRT7 VIM

Biological processes related to Epithelial-Myoepithelial Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.71 HMGA2 NR4A3 TAF15 TP53
2 intrinsic apoptotic signaling pathway GO:0097193 9.37 HRAS TP53
3 cell aging GO:0007569 9.32 HRAS TP53
4 cellular response to gamma radiation GO:0071480 9.26 HRAS TP53
5 viral process GO:0016032 9.26 FBXW7 KRT7 TP53 VIM
6 positive regulation of cell cycle arrest GO:0071158 9.16 HMGA2 TP53
7 positive regulation of gene expression GO:0010628 8.92 HMGA2 HRAS TP53 VIM

Molecular functions related to Epithelial-Myoepithelial Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 histone acetyltransferase binding GO:0035035 9.16 NR4A3 TP53
2 cAMP response element binding GO:0035497 8.96 HMGA2 NR4A3
3 keratin filament binding GO:1990254 8.62 KRT14 VIM

Sources for Epithelial-Myoepithelial Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....